-
1
-
-
84876740954
-
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
-
published online March 15.
-
Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013, published online March 15. http://dx.doi.org/10.1016/S1473-3099(13)70033-1.
-
(2013)
Lancet Infect Dis
-
-
Lawitz, E.1
Lalezari, J.P.2
Hassanein, T.3
-
2
-
-
33747797031
-
Treating viral hepatitis C: efficacy, side effects, and complications
-
Manns MP, Wedemeyer H, Cornberg M Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55:1350-1359.
-
(2006)
Gut
, vol.55
, pp. 1350-1359
-
-
Manns, M.P.1
Wedemeyer, H.2
Cornberg, M.3
-
3
-
-
0032547938
-
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group
-
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-1492.
-
(1998)
N Engl J Med
, vol.339
, pp. 1485-1492
-
-
McHutchison, J.G.1
Gordon, S.C.2
Schiff, E.R.3
-
4
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
-
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
-
5
-
-
0344201903
-
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
-
Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189.
-
(2003)
Nature
, vol.426
, pp. 186-189
-
-
Lamarre, D.1
Anderson, P.C.2
Bailey, M.3
-
6
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
Poordad F, McCone JJ, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone, J.J.2
Bacon, B.R.3
-
7
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
-
8
-
-
84871487025
-
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
-
van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012, 308:2584-2593.
-
(2012)
JAMA
, vol.308
, pp. 2584-2593
-
-
van der Meer, A.J.1
Veldt, B.J.2
Feld, J.J.3
-
9
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
-
(2011)
N Engl J Med
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
-
10
-
-
84863519517
-
Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 455 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting
-
(abstr).
-
Hezode C, Dorival C, Zoulim F, et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 455 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. Hepatology 2012, 56:51. (abstr).
-
(2012)
Hepatology
, vol.56
, pp. 51
-
-
Hezode, C.1
Dorival, C.2
Zoulim, F.3
-
11
-
-
84873275651
-
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting
-
Maasoumy B, Port K, Markova AA, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 2013, 8:e55285.
-
(2013)
PLoS One
, vol.8
-
-
Maasoumy, B.1
Port, K.2
Markova, A.A.3
-
12
-
-
84874107832
-
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
-
Lange CM, Zeuzem S Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013, 58:583-592.
-
(2013)
J Hepatol
, vol.58
, pp. 583-592
-
-
Lange, C.M.1
Zeuzem, S.2
-
13
-
-
84878976866
-
Sofosbuvir with peginterferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
-
published online March 15.
-
Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with peginterferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013, published online March 15. http://dx.doi.org/10.1016/S0140-6736(13)60247-0.
-
(2013)
Lancet
-
-
Kowdley, K.V.1
Lawitz, E.2
Crespo, I.3
-
14
-
-
84871814966
-
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
-
Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013, 368:34-44.
-
(2013)
N Engl J Med
, vol.368
, pp. 34-44
-
-
Gane, E.J.1
Stedman, C.A.2
Hyland, R.H.3
-
15
-
-
84872022905
-
High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A Inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3
-
LB-2.
-
Sulkowski M, Gardiner DF, Rodriguez-Torres M, et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A Inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. Hepatology 2012, 56. LB-2.
-
(2012)
Hepatology
, vol.56
-
-
Sulkowski, M.1
Gardiner, D.F.2
Rodriguez-Torres, M.3
|